3.9 Article

Even chained acylcarnitines predict long-term cardiovascular prognosis in patients with chest pain and non-obstructive coronary artery disease

出版社

ELSEVIER
DOI: 10.1016/j.ijcrp.2022.200134

关键词

Acylcarnitines; Non-obstructive coronary artery disease; Outcomes; Metabolism

向作者/读者索取更多资源

This study explored the predictive role of carnitine metabolites in cardiovascular disease and all-cause mortality among patients with non-obstructive coronary artery disease. The results showed that serum levels of acetyl, octanoyl-, and palmitoylcarnitine were associated with CVD mortality. Higher levels of acetyl- and palmitoylcarnitine were also linked to increased risk of all-cause mortality.
Background: Acylcarnitines are essential for mitochondrial fatty acid oxidation. Earlier studies suggest that impaired energy metabolism may be implicated in the pathogenesis of microvascular angina. We explored metabolites from the carnitine pathway as predictors of cardiovascular disease (CVD) - and all-cause mortality among patients with non-obstructive coronary artery disease (NOCAD). Methods: A total of 1046 patients with suspected stable coronary syndrome underwent coronary angiography during 2000???2004, with findings of NOCAD. Serum levels of 8 selected carnitine metabolites were analyzed through liquid chromatography tandem mass spectrometry. Associations with CVD- and all-cause mortality were assessed by multivariable Cox regression models. Results: Median age at inclusion was 57 years. 51.5% were men. During median (25th- 75th percentiles), 14.1 (13.2???15.4) years of follow-up, 5.7% of the participants died from CVD and the incidence of all-cause mortality was 17.3%. Serum acetyl, octanoyl- and palmitoylcarnitine predicted CVD mortality with multivariable HR and 95% CI (per SD increment log transformed) of 1.36 (1.01???1.83), 1.49 (1.15???1.93) and 2.07 (1.49???2.85), p < 0.04, respectively. Higher serum acetyl- and palmitoylcarnitines were also associated with increased risk of allcause mortality (HR (95% CI): 1.27 (1.01???1.50), and 1.51 (1.26???1.81), p < 0.007. Baseline levels of the precursors trimethyllysine and ??-butyrobetaine, carnitine or the odd chained propionylcarnitine and (iso)valerylcarnitine were not associated with adverse outcomes. Conclusion: Elevated serum even-chained acylcarnitines predicted adverse long-term prognosis in NOCAD. The strongest risk estimates were observed for palmitoylcarnitine, which predicted both CVD- and all-cause mortality after extensive multivariable adjustments. Underlying pathomechanisms should be further elucidated.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据